Form 4: PMV Pharmaceuticals Director Receives Stock Option Grant

Director Laurie Stelzer was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity compensation plan.

Summary

• Director Laurie Stelzer received a grant of 42,000 stock options on June 4, 2026.
• The options have an exercise price of $1.19 per share.
• The options are set to expire on June 4, 2036.
• The grant vests on the earlier of June 4, 2027, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $1.19 may be subject to market fluctuations relative to the company's future performance.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon potential future exercise.

Next Steps

• Vesting of options on June 4, 2027, or the next annual meeting.

Key Dates

Keywords

PMVP, PMV Pharmaceuticals, Form 4, Director Compensation, Stock Options, Insider Trading